MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors MaxCyte's Flow Electroporation(R) Technology will support efficient gene delivery to advance Moonlight Bio's engineered T cell therapies GlobeNewswire October 06, 2025 ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing […]